REMEDY, Research Ethics in Medicine Study Group works on ethics and policy of biomedical research. Our team has expertise in philosophy, biology, biomedical engineering, mathematics, biostatistics and public health.
Our main area of interest is research with the participation of vulnerable populations, including paediatric research. We also concentrate particularly on analysis of the factors influencing biomedical research in Central and Eastern Europe.
Karolina Strzebońska will present poster about dose expansion cohorts in pediatric phase I cancer research at the Evidence Live conference in Oxford. Marcin Waligóra will be speaking obout our recent study in the Department of Bioethics of The National Institutes of Health, the Johns Hopkins Berman Institute of Bioethics Seminar Series and the Department of Bioethics at Clarkson University.
STAT about our recent study: New study raises questions about early-stage cancer therapies for children.
Read a commentary by Jonathan Kimmelman on our findings: Risk/Benefit in Pediatric Phase 1 Cancer Trials: Noble Lie? Part 1 and Part 2.
Link to the study published in PLOS Medicine: Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.